A common malnutrition screening tool called MUST is not accurate enough for patients with newly diagnosed stomach and esophageal cancer, according to a 2026 validation study of 80 patients. The MUST tool missed malnutrition in 24% of patients who actually had it and incorrectly flagged 10% who didn’t. Gram Research analysis shows doctors should use more thorough nutrition assessments for cancer patients rather than relying on quick screening tools alone.
A new study found that a popular tool doctors use to screen for malnutrition isn’t working well enough for patients with newly diagnosed stomach and esophageal cancer. Researchers compared the Malnutrition Universal Screening Tool (MUST) with a more detailed assessment method called Patient-Generated Subjective Global Assessment (PG-SGA) in 80 cancer patients. The MUST tool missed about 24% of patients who actually had malnutrition risk and incorrectly flagged 10% who didn’t. According to Gram Research analysis, this means doctors treating stomach cancer patients may need better screening methods to catch nutrition problems early, which is important because malnutrition can make cancer treatment less effective.
Key Statistics
A 2026 validation study of 80 patients with newly diagnosed esophago-gastric cancer found that the MUST screening tool had only 61.2% sensitivity for detecting malnutrition risk, missing nearly 4 out of 10 patients who actually needed nutrition support.
According to research published in the Journal of the Academy of Nutrition and Dietetics, the MUST tool misclassified 24% of esophago-gastric cancer patients as low-risk for malnutrition when they actually had significant nutrition problems.
A 2026 study comparing two nutrition assessment methods in 80 cancer patients found that weight loss was a moderately strong predictor of malnutrition (correlation 0.653), while BMI alone showed only weak association with true malnutrition status.
The Quick Take
- What they studied: Whether a quick malnutrition screening tool called MUST accurately identifies stomach and esophageal cancer patients who are at risk of malnutrition
- Who participated: 80 patients with newly diagnosed stomach or esophageal cancer who were waiting to start cancer treatment at a hospital in London between 2011 and 2013
- Key finding: The MUST tool only correctly identified malnutrition risk 61% of the time and missed about 24% of patients who actually had nutrition problems. It also incorrectly flagged 10% of patients as having malnutrition when they didn’t.
- What it means for you: If you or a loved one is diagnosed with stomach or esophageal cancer, doctors should use more thorough nutrition assessments beyond just the MUST tool to catch malnutrition early, since poor nutrition can affect cancer treatment success
The Research Details
Researchers recruited 80 patients with newly diagnosed stomach or esophageal cancer at a London hospital. Each patient was screened using two different methods: the quick MUST tool and a more detailed assessment called PG-SGA, which involves patient questions and physical measurements. The researchers compared how well MUST matched the results from PG-SGA to see if MUST was accurate enough to use alone.
The MUST tool is designed to be fast and simple—it looks at three things: body mass index (BMI), recent weight loss, and whether the patient is acutely ill. The PG-SGA is more thorough and includes detailed questions about food intake, symptoms affecting eating, and physical examination. By comparing these two methods, researchers could see where MUST was getting it wrong.
Cancer patients often develop malnutrition because the disease and treatment affect their ability to eat and absorb nutrients. Catching malnutrition early is critical because it can weaken patients and make cancer treatment less effective. Doctors need screening tools that are both quick and accurate. This study matters because it shows that using a fast but inaccurate tool might actually be worse than no screening at all—it could miss patients who need help while wasting resources on false alarms.
This was a well-designed validation study that directly compared two assessment methods in real cancer patients. The researchers used standard statistical measures (sensitivity, specificity, predictive values) to evaluate accuracy. The study was conducted at a reputable cancer hospital with consistent patient recruitment over 18 months. However, the sample size of 80 patients is moderate, and the study was conducted over a decade ago, so current practices may have evolved. The study was published in a peer-reviewed nutrition journal, indicating it met scientific standards.
What the Results Show
The MUST tool agreed with the more detailed PG-SGA assessment in only 66% of patients (53 out of 80). This means it was wrong about one-third of the time—a significant failure rate for a screening tool.
The sensitivity of MUST was 61.2%, meaning it correctly identified only about 6 out of 10 patients who actually had malnutrition risk. This is particularly concerning because missing malnutrition in cancer patients can have serious consequences. The specificity was 74.2%, meaning it correctly identified patients without malnutrition risk about 3 out of 4 times.
Most troubling, MUST misclassified 19 patients (24%) as being at low risk when they actually had malnutrition risk. These are the “false negatives”—patients who needed help but the tool said they didn’t. Additionally, 8 patients (10%) were incorrectly flagged as at-risk when they weren’t—these false positives can lead to unnecessary interventions.
The researchers found that weight loss was a better predictor of malnutrition than BMI alone. Patients who had lost more weight were more likely to have malnutrition according to the detailed assessment. However, BMI by itself showed only a weak connection to malnutrition status. This suggests that the MUST tool’s reliance on BMI may be part of why it’s not working well in cancer patients—weight loss history appears more important.
The MUST tool was originally developed and validated for general hospital populations, not specifically for cancer patients. This study shows that tools validated in one patient group don’t automatically work well in another. Previous research has shown that cancer patients have unique nutritional challenges compared to other hospitalized patients, so it makes sense that a general screening tool might not be sensitive enough. This finding supports the need for cancer-specific screening approaches.
The study included only 80 patients from one hospital in the UK, so results may not apply to all cancer patients everywhere. The study was conducted from 2011-2013, so practices and patient populations may have changed. The researchers only looked at patients with newly diagnosed cancer awaiting treatment—results might differ for patients already undergoing treatment or in later cancer stages. The study didn’t test whether using PG-SGA instead of MUST actually improved patient outcomes, only that it was more accurate at identifying malnutrition risk.
The Bottom Line
For patients with newly diagnosed stomach or esophageal cancer: Ask your medical team to use a thorough nutrition assessment (like PG-SGA) rather than relying only on quick screening tools like MUST. This is a strong recommendation based on this validation study. For healthcare providers: The MUST tool should not be used as the sole screening method for esophago-gastric cancer patients; more comprehensive assessment is needed. Confidence level: High, based on direct comparison with a validated reference standard.
This finding is most important for patients with stomach or esophageal cancer and their doctors. Oncologists, nutritionists, and cancer care teams should be aware that standard screening tools may miss malnutrition in this population. Patients with other types of cancer should discuss with their care team whether MUST is appropriate for their situation. General hospital patients without cancer may still benefit from MUST screening, as this study only evaluated cancer patients.
Malnutrition screening should happen at the time of cancer diagnosis, before treatment begins. If malnutrition is identified, nutritional support can be started immediately. Benefits of proper nutrition support typically appear within weeks as patients’ strength and treatment tolerance improve. The goal is to prevent malnutrition from developing rather than treating it after it’s already caused problems.
Frequently Asked Questions
Is the MUST screening tool reliable for detecting malnutrition in stomach cancer patients?
No. A 2026 study of 80 esophago-gastric cancer patients found MUST had only 61% sensitivity and missed malnutrition in 24% of patients who actually had it. More comprehensive assessments like PG-SGA are needed for accurate screening in cancer populations.
What percentage of stomach cancer patients does MUST incorrectly identify as not having malnutrition?
The study found MUST misclassified 24% of patients (19 out of 80) as being at low malnutrition risk when they actually had significant nutrition problems requiring intervention.
Should cancer patients ask for a different nutrition screening tool than MUST?
Yes. For esophago-gastric cancer patients specifically, research shows more thorough assessments like Patient-Generated Subjective Global Assessment (PG-SGA) are more accurate. Ask your oncology team for comprehensive nutrition evaluation rather than quick screening tools alone.
Why is weight loss a better indicator of malnutrition than BMI in cancer patients?
This study found weight loss showed moderate correlation (0.653) with true malnutrition status, while BMI showed only weak association. Cancer patients’ weight loss reflects active nutritional decline, making it a more sensitive indicator than BMI alone.
What should I do if I’m diagnosed with esophageal or stomach cancer to ensure proper nutrition screening?
Request a comprehensive nutrition assessment from your oncology team at diagnosis. Bring documentation of recent weight changes and eating difficulties. Don’t rely solely on quick screening results—advocate for thorough evaluation before starting cancer treatment.
Want to Apply This Research?
- Track weekly weight and any changes in appetite or ability to eat. Users should log: current weight, percentage change from baseline, number of meals eaten per day, and any symptoms affecting eating (nausea, difficulty swallowing, early fullness). This data can be shared with healthcare providers to supplement formal nutrition assessments.
- Users diagnosed with esophago-gastric cancer should request a comprehensive nutrition assessment from their care team rather than accepting a quick screening tool result alone. They can use the app to document their nutrition status, food intake, and symptoms to bring to appointments, ensuring their care team has complete information for assessment.
- Establish a baseline nutrition profile at diagnosis including weight, dietary intake, and eating-related symptoms. Track these weekly throughout cancer treatment. Flag significant changes (5%+ weight loss in a month, major appetite changes) to alert users to discuss with their healthcare team. Compare trends over time to assess whether nutrition interventions are working.
This article summarizes research findings and is not medical advice. Malnutrition screening and assessment should only be performed by qualified healthcare professionals. If you have been diagnosed with esophageal or stomach cancer, work with your oncology team and registered dietitian to determine the most appropriate nutrition assessment and support for your individual situation. Do not delay or avoid medical evaluation based on this information. Always consult with your healthcare provider before making changes to your nutrition care plan.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.